SCHEMBL6360290

SCHEMBL6360290

NC(=O)c1c(O)ccc(N)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40
MMP2 P08253 1/20 0.38
HSD17B10 Q99714 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
HDAC3 O15379 1/20 0.37
IDO1 P14902 1/20 0.37
EP300 Q09472 1/20 0.37
KAT2B Q92831 1/20 0.37
KAT8 Q9H7Z6 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
TSHR P16473 1/20 0.37
THRB P10828 3/20 0.35
GAA P10253 2/20 0.35
CYP3A4 P08684 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11054505 0.83 HSD17B10 (0.41) MMP2HSD17B10HPGDKDM4EALDH1A1
SCHEMBL29438133 0.82 CA12 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3MMP2
SCHEMBL17262955 0.82 CA12 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3MMP2
SCHEMBL2000711 0.80 HSD17B10 (0.46) HSD17B10HPGDKDM4EALDH1A1MAPT
SCHEMBL206180 0.78 DPP4 (0.47) CSNK2A1MMP2HSD17B10HPGDKDM4E
SCHEMBL30366773 0.77 KDM4E (0.46) HSD17B10HPGDKDM4EALDH1A1MAPT
SCHEMBL10137909 0.77 ERN1 (0.39) MMP2ERN1
SCHEMBL10119565 0.75 MMP2 (0.33) MMP2IKBKB
SCHEMBL744309 0.75 CA12 (0.59) HSD17B10HPGDKDM4EALDH1A1MAPT
SCHEMBL17774953 0.75 IKBKB (0.40) HSD17B10HPGDKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143366-A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143366-A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders SOST, BMP2, BMP4 CSNK2A2 4018/4885CSNK2B 4042/4885CSNK2A1 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.